Compare Gilead Sciences, Inc. (GILD) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nuwellis Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Gilead Sciences, Inc. is far larger — about 82909.1× Nuwellis Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Nuwellis Inc for 26 Days on average.
| GILD | NUWE | |
|---|---|---|
Market Cap | $182.40B | $2.20M |
Volume | 4,469,821 | 121,544 |
Sector | Health | Health |
52-Week High | $155.80 | $146.65 |
52-Week Low | $117.18 | $0.68 |
Typical Hold Time | 111 Days | 26 Days |
Enterprise Value | $205.46B | -$1.52M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
